Groupe la Francaise Has $4.69 Million Stock Position in AbbVie Inc. $ABBV

Groupe la Francaise raised its holdings in AbbVie Inc. (NYSE:ABBV) by 34.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 25,376 shares of the company’s stock after acquiring an additional 6,466 shares during the quarter. Groupe la Francaise’s holdings in AbbVie were worth $4,690,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ABBV. TD Capital Management LLC boosted its stake in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA acquired a new position in shares of AbbVie during the second quarter valued at about $25,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the 2nd quarter worth about $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie in the 2nd quarter valued at about $36,000. Finally, Bear Mountain Capital Inc. raised its stake in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 2.6%

AbbVie stock opened at $230.32 on Thursday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The firm’s 50-day simple moving average is $227.98 and its 200 day simple moving average is $207.76. The stock has a market cap of $407.06 billion, a PE ratio of 174.48, a price-to-earnings-growth ratio of 1.22 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ABBV. Raymond James Financial set a $256.00 target price on AbbVie in a research report on Monday, November 3rd. Daiwa Capital Markets upgraded shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective on the stock in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. JPMorgan Chase & Co. boosted their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.